Volume 28, Issue 1 (April 2021)                   J Birjand Univ Med Sci 2021, 28(1): 84-87 | Back to browse issues page

Research code: 123
Ethics code: 123


XML Persian Abstract Print


1- Student Research Committee, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran , nafiseherfanian64@yahoo.com
2- Cardiovascular Diseases Research Center, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
Abstract:   (2880 Views)
The symptoms of COVID-19, caused by the newly known type of coronavirus, vary widely from asymptomatic, mild to severe respiratory infection leading to hospitalization or death of patients. To date, no specific drug has been reported for the treatment of patients affected by this virus. One of the approaches adopted for the treatment of this disease is the use of plasma therapy, which contains antibodies against the virus. Following of the plasma therapy have not been reported any serious side effects. Currently, the numbers of these studies are limited, and evaluation of the larger population studies can provide stronger evidence for treating physicians about the effectiveness of this therapeutic approach.
Full-Text [PDF 337 kb]   (754 Downloads) |   |   Full-Text (HTML)  (433 Views)  
Type of Study: Letter to Editor | Subject: Immunology
Received: 2020/10/4 | Accepted: 2020/12/18 | ePublished ahead of print: 2021/01/20 | ePublished: 2021/03/5

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.